PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL® Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis
Sponsor: HAL Allergy
Listed as NCT01438463, this PHASE2 trial focuses on Allergic Rhinitis and Allergic Rhinoconjunctivitis and remains completed. Sponsored by HAL Allergy, it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HAL Allergy
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Almere Stad, Netherlands , Arnhem, Netherlands , Barcelona, Spain , Berlin, Germany , Bonn, Germany , Chemnitz, Germany , Dordrecht, Netherlands , Dortmund, Germany , Duisburg, Germany , Düren, Germany and 20 more locations